Valneva and Serum Institute End License Agreement for Chikungunya Vaccine

Valneva SE and the Serum Institute of India (SII) have mutually agreed to terminate their licensing agreement for Valneva’s single-dose chikungunya vaccine. The decision allows Valneva to regain full rights to the vaccine and assume direct control over manufacturing, supply chain management, and commercialization, particularly in endemic and high-risk regions.

Valneva said the move aligns with its strategy to accelerate vaccine access in countries most affected by chikungunya, especially low- and middle-income countries. This objective is supported by Valneva’s funding agreement with the Coalition for Epidemic Preparedness Innovations (CEPI), signed in July 2024 with co-funding from the European Union.

Chikungunya is a mosquito-borne viral disease that causes fever and severe, often long-lasting joint pain. Since its global re-emergence in 2004, the virus has spread to more than 110 countries, with over 3.7 million cases reported in the Americas between 2013 and 2023. The World Health Organization has identified chikungunya as a major public health concern, with its burden expected to rise due to climate change.

02-01-2026